

**EXTENSION OF TIME GRANTED BY MOH  
TO PROVIDE WRITTEN REPRESENTATIONS**

---

**1. Introduction**

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**") refers to:

- (a) its announcements dated 30 November 2023, 13 December 2023, 15 December 2023, 17 January 2024, 23 January 2024, 8 April 2024, 28 May 2024, 18 June 2024, 30 August 2024, 6 September 2024, 13 September 2024, 1 October 2024 and 14 January 2025 relating to, *inter alia*, the renewal by the Ministry of Health ("**MOH**") of the Company's cord blood banking service and human tissue banking licence for a period of one (1) year with effect from 14 January 2025 (the "**CBBS Licence**");
- (b) its announcements dated 8 April 2024, 25 March 2025, 2 April 2025 and 14 May 2025 relating to, *inter alia*, the Company sending over 200 samples of donated cord blood units from the five (5) cryogenic storage tanks under investigation by the Ministry of Health which were found to be at low risk of being adversely affected by temperature excursions for testing across multiple third-party laboratories; and
- (c) its announcement dated 1 October 2025 (the "**MOH Notice Announcement**") relating to, *inter alia*, the receipt by the Company of a letter from MOH of the Director-General of Health's intention to suspend the Company's CBBS Licence for a period of one (1) year (the "**MOH Notice**").

*Unless defined, all capitalised terms used and not defined in this announcement shall have the same meanings as defined in the MOH Notice Announcement.*

**2. Extension of Time granted**

As stated in the MOH Notice Announcement, the Company has 14 days from the date of the MOH Notice (i.e. until 13 October 2025) to make representations to MOH in relation to the contents of the MOH Notice.

The Board wishes to update that:

- (a) On 6 October 2025, the Company made an application to MOH for an extension of the 14-day period for the submission of its written representations in relation to the contents of the MOH Notice.
- (b) The Company was informed by MOH on 12 October 2025 that the Company has been granted an extension of time from 13 October 2025 to **27 October 2025** to submit its written representations to the Director-General.

The Company is continuing to seek advice on the appropriate response to the Notice and will provide an update in due course.

**3. Stoppage of Collection, Testing, Processing and/or Storage of new Cord Blood Units**

The Company wishes to also announce that, since 30 September 2025 (i.e. one (1) day after the MOH Notice), the Company has stopped the collection, testing, processing and/or storage of any new cord blood units. The Company had voluntarily done so, notwithstanding that the suspension

of the Company's CBBS Licence would only take effect upon the service of a subsequent notice of decision by MOH, and upon consideration of the representations by the Company.

#### **4. Cautionary Statement**

The Company will update its shareholders if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

In the meantime, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the action they should take.

By order of the Board

**CORDLIFE GROUP LIMITED**

Cheok Hui Yee  
Goh Xun Er  
Company Secretaries

13 October 2025